<DOC>
	<DOCNO>NCT02208167</DOCNO>
	<brief_summary>This phase 1 , single-site study evaluate safety immunologic virologic efficacy ex vivo expand HIV-1 multi-antigen specific T-cell ( HXTC ) therapy HIV-infected individual viral suppression antiretroviral therapy ( ART ) .</brief_summary>
	<brief_title>Phase I Study HIV 1 Antigen Expanded Specific T Cell Therapy</brief_title>
	<detailed_description>The main hypothesis study administration autologous ex vivo expand HIV-specific T-cells ( HXTCs ) prim recognize multiple HIV-1 antigen HIV-infected participant initiated ART acute chronic HIV infection safe , increase HIV-1 antigen specific T-cell immune response decrease low level viremia . In addition , secondary objective : 1 . Determine feasibility manufacture HXTC participant start cART acute chronic HIV infection . 2 . Explore ability autologous ex vivo expand HIV-1 specific T-cells ( HXTC ) increase HIV-1 specific immune response participant initiated cART acute chronic HIV infection . 3 . Explore ability autologous ex vivo expand HIV-1 specific T-cells ( HXTC ) impact latent HIV infection measure quantitative viral outgrowth assay ( QVOA ) integrate proviral DNA quantification , low level viremia measure single copy assay ( SCA ) participant initiate cART acute chronic HIV infection .</detailed_description>
	<criteria>1 . ≥ 18 year ≤65 year age 2 . Confirmation HIV 1 infection Chronic HIV infection ( CHI ) define documentation positive HIV test result license ELISA test kit confirm Western blot Multispot HIV 1/HIV 2 assay prior screen . HIV culture , HIV antigen , plasma HIV RNA , second antibody test method ELISA acceptable alternative confirmatory test . Acute HIV infection ( AHI ) define : 1 ) negative indeterminate enzyme immunoassay ( EIA ) plus reproducibly detectable HIV amplification method , 2 ) positive 4th generation HIV Ag/Ab Combination assay either negative/indeterminate HIV rapid test negative/indeterminate Western blot , 3 ) negative HIV RNA test within 45 day positive EIA ART initiation . Note : HIV definition pertinent time diagnosis treatment initiation . 3 . AHI participant define HIV infect patient suppressive ART initiate within 45 day AHI diagnosis define protocol section 5.1.2 . 4 . CHI participant define HIV infect patient initiated ART chronic HIV define protocol section 5.1.2 . 5 . On potent antiretroviral therapy , define least 2 nucleoside/nucleotide reverse transcriptase inhibitor plus nonnucleoside reverse transcriptase inhibitor , integrase inhibitor , protease inhibitor without interruption ( define miss dos two ( 2 ) consecutive day four ( 4 ) cumulative day ) 12 week prior entry . Other potent fully suppressive antiretroviral combination consider case case basis . Prior change elimination medication easier dose schedule , intolerance , toxicity , reason permit alternative suppressive regimen maintain . 6 . Stable ART regimen minimum 3 month . NOTE : The ART regimen define current treatment guideline . Participants may one change ART regimen tolerance , change guideline , dose simplification . 7 . Ability willingness participant continue cART throughout study . 8 . Plasma HIV 1 RNA detect limit conventional assay ( limit detection : 75 , 50 , 40 , 20 copies/mL ) ˃1 year . A single unconfirmed plasma HIV RNA ˃ limit detection ˂ 1000 c/mL allow within prior 12 month ; none precede 6 month . 9 . Plasma HIV 1 RNA ˂ 50 copies/mL screening . 10 . CD4+ cell count ˃ 350 cells/mm3 screening . 11 . No active HCV infection ( measureable HCV RNA ) within 90 day enrollment . 12 . No active HBV infection ( measureable HBV DNA HBVsAg+ ) within 90 day enrollment . 13 . All female participant participate sexual activity could lead pregnancy must agree use least two follow reliable method birth control ( least one barrier method ) least 21 day prior study entry 12 week last dose study product : condom ( male female ) without spermicidal agent , diaphragm cervical cap spermicide , Intrauterine Device , hormonebased contraceptive , tubal ligation , NuvaRing . 14 . All male participant participate sexual activity could lead pregnancy must agree use condom least 21 day prior study entry 12 week last dose study product . 15 . Ability willingness subject give write informed consent . 16 . Ability willingness provide adequate locator information . 17 . Ability willingness communicate effectively study personnel ; consider reliable , willing , cooperative term compliance Protocol requirement . 18 . Adequate vascular access HXTC infusion leukapheresis . 19 . Potential participant must adequate organ function indicate follow laboratory value : Absolute neutrophil count ( ANC ) : ≥ 1,500 /mcL Platelets : ≥ 125,000 / mcL Hemoglobin : ≥ 12 g/dL Coagulation : Prothrombin Time INR : ≤ 1.5 time upper limit normal ( ULN ) Chemistry K+ level : Within normal limit Renal : Serum creatinine ( calculated creatinine clearance* creatinine &gt; 1.3 ULN ) : ≤ 1.3 time upper limit normal ( ULN ) ; OR Creatinine clearance* ≥ 60 mL/min potential participant creatinine level &gt; 1.3 time institutional ULN Hepatic Serum total bilirubin : Total bilirubin &lt; 1.5 time upper limit normal range . If total bilirubin elevate , direct bilirubin must &lt; 2 time ULN range . NOTE : If participant atazanavir contain therapy direct bilirubin measure instead total bilirubin must ≤ 1.0mg/dL . AST ( SGOT ) ALT ( SGPT ) : ≤ 2.0 time ULN Alkaline Phosphatase : ≤ 2.5 time ULN *Creatinine clearance calculate per institutional standard . 1 . Prior use HIV immunotherapy vaccine within 12 month prior Screening . 2 . Use follow within 90 day prior entry : immunomodulatory , cytokine , growth stimulate factor systemic corticosteroid , cyclosporine , methotrexate , azathioprine , antiCD25 antibody , IFN , interleukin 2 ( IL 2 ) , Coumadin , warfarin , Coumadin derivative anticoagulant . 3 . Received infusion blood product , immune globulin , hematopoietic growth factor within 90 day prior study entry . 4 . Pregnancy breastfeed . 5 . History evidence severe illness , malignancy , immunodeficiency HIV , condition would make subject unsuitable study opinion investigator . 6 . Use topical steroid total area exceed 0.5mg/kg/day within 30 day prior Screening . 7 . Any active malignancy may require chemotherapy radiation therapy . 8 . Compulsorily detain ( involuntarily incarcerate ) treatment either psychiatric illness physical illness , e.g. , infectious disease . Prisoner recruitment participation permit . 9 . Any licensed experimental nonHIV vaccination ( e.g. , hepatitis B , influenza , pneumococcal polysaccharide ) within 4 week prior study entry . 10 . Unable person available drive participant home infusion visit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Antigen Expanded Specific T Cell Therapy</keyword>
	<keyword>HXTC</keyword>
	<keyword>Antiretroviral Therapy</keyword>
	<keyword>Acute HIV infection</keyword>
	<keyword>Chronic HIV infection</keyword>
	<keyword>Leukapheresis</keyword>
</DOC>